Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Chip is one of the fastest-growing Fintech companies in the UK. Chip has built an app that uses the user's banking app to make personalised decisions about their money. Its user base has doubled since its previous fundraising in 2018. The company has 153,000 accounts, and it has processed more than £130m of savings. ChipX is the company's revolutionary returns platform and it has a waiting list of more than 50,000 people. The company is a winner of the British Bank Award, 2 Crowdcube awards, and 1 World Banking Award. It has welcomed many management executives from Funding Circle, Monzo, and Purple Bricks. Chip is now scaling with market-leading returns on ChipX. It aims to build the biggest savings account in the world. With the proceeds, the company will double its team and expand ChipX in the €10 trillion European savings market.
days to go:
Expired
investment:
£3,768,260
Premium popsicles partnered with Pimm's producers and available as alcohol and alcohol-free. POPS has pioneered a contemporary and innovative concept within the ice cream industry. Since inception, their business and product range has grown and now consist of popsicles made from real fruit, all natural ingredients and are less than 60 calories. One of their most notable products is the champagne ice popsicle, a world first.
POPS have generated sales of more than £590k in the first half of 2018, which is equivalent to their total sales in 2017. Their products are available at major retailers, including Ocado and Tesco. As well as regional locations, such as Spar, Musgraves, Whole Foods and 500 other independent stockists. The range is also sold at festivals, sporting events, cinemas, theatres and leisure groups.
Funds are being raised to launch new product ranges in 2019 that are aimed at a wider target audience and suitable in most situations. POPS aims to ensure their products meet consumer trends in regards to health and portion sizes.
days to go:
Expired
investment:
£479,550
Creating alcoholic beverages for the health-conscious consumer. SkinnyBrands produces 'better-for-you' alternatives for those looking to reduce the number of calories they consume, have gluten intolerances, or prefer to live a healthy and actively lifestyle but still love drinking beer.
In 2016/17, turnover was £445k and the company is now expecting a YoY increase of 211%. This will result in a turnover of £1.4m. SkinnyBrands's monetisation strategy involves selling their products through retailers worldwide via multiple distribution channels. Due to the business's rapid growth, this investment round will allow the company to make key hires in key markets such as the UK, USA and Australia, as well establish further distribution rights and stockists to sell their products.
days to go:
Expired
investment:
£437,599
Rebel Energy (RE) is an energy supplier on a mission to address inequality and provide everyone with easy access to clean and affordable energy, to eventually eliminate fuel poverty. RE claims that fuel poverty led to 16,500+ cold-related deaths in the UK in 2018. RE argues that as the UK home electricity market enters a phase of growth in a post-COVID world, it will be focused on offering reliable customer service and develop strategies that help people who are struggling with their electricity bills. The company has applied for a B Corporation accreditation. RE asserts that its customer support systems are automated and can handle multiple queries simultaneously. It plans to offer a weekly direct debit payment option. RE will use the investment to grow its business across different verticals.
days to go:
Expired
investment:
£503,810
miiCARE is a MedTech specialising in AI applied to geriatrics (elderly care). Its key product miiCUBE offers cutting-edge home-based and customised healthcare, helping the elderly enjoy their independence while being comprehensively connected to their families, friends, and neighbours. The company aims to provide these benefits to one billion people by 2028, comprising older people, family members and carers. Till date, miiCARE has secured partnerships with the UK’s largest NHS trust, Ebbsfleet Garden City, O2, Bristol Careline and Microsoft, and won multiple social impacts and digital health awards during the last 12 months. Funds raised will be used mainly for fulfilling pre-orders and close interests for large contracts with corporates, marketing and logistics, product development, sales and salaries.
days to go:
Expired
investment:
£103,672
Charm is a peer-to-peer impact investment platform that allows a user to use his/her investments to drive positive change in the world while earning a financial return. Morgan Stanley estimates that 85% of people are interested in sustainable investing. Charm enables individuals to fund projects led by high-impact entrepreneurs selling clean energy solutions in developing economies. Users can view their investments on the company's transparent, personalised impact investment dashboard, as well as, earn social, environmental and financial bottom line returns for their contributions. The company secured a £496,000 grant funding to develop its platform, refine its offering & provide growth capital. It is in the process of becoming an appointed representative of a Financial Conduct Authority (FCA) authorised entity post this funding round. It will use the investment to expand its team, develop its platform, and raise brand awareness.
days to go:
Expired
investment:
£273,720
